- Home
- GNPX vs CYCC Comparison
GNPX vs CYCC Comparison
Compare GNPX & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- CYCC
- Stock Information
- Founded
- GNPX 2009
- CYCC 1992
- Country
- GNPX United States
- CYCC Malaysia
- Employees
- GNPX N/A
- CYCC N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- GNPX Health Care
- CYCC Health Care
- Exchange
- GNPX Nasdaq
- CYCC Nasdaq
- Market Cap
- GNPX 6.6M
- CYCC 7.8M
- IPO Year
- GNPX 2018
- CYCC N/A
- Fundamental
- Price
- GNPX $0.28
- CYCC $3.75
- Analyst Decision
- GNPX
- CYCC
- Analyst Count
- GNPX 0
- CYCC 0
- Target Price
- GNPX N/A
- CYCC N/A
- AVG Volume (30 Days)
- GNPX 3.4M
- CYCC 465.6K
- Earning Date
- GNPX 08-08-2025
- CYCC 08-13-2025
- Dividend Yield
- GNPX N/A
- CYCC N/A
- EPS Growth
- GNPX N/A
- CYCC N/A
- EPS
- GNPX N/A
- CYCC N/A
- Revenue
- GNPX N/A
- CYCC $14,000.00
- Revenue This Year
- GNPX N/A
- CYCC $137.21
- Revenue Next Year
- GNPX N/A
- CYCC N/A
- P/E Ratio
- GNPX N/A
- CYCC N/A
- Revenue Growth
- GNPX N/A
- CYCC N/A
- 52 Week Low
- GNPX $0.20
- CYCC $3.08
- 52 Week High
- GNPX $3.97
- CYCC $597.60
- Technical
- Relative Strength Index (RSI)
- GNPX 55.29
- CYCC 28.20
- Support Level
- GNPX $0.25
- CYCC $3.17
- Resistance Level
- GNPX $0.27
- CYCC $3.97
- Average True Range (ATR)
- GNPX 0.03
- CYCC 0.59
- MACD
- GNPX 0.00
- CYCC 1.36
- Stochastic Oscillator
- GNPX 90.71
- CYCC 36.48
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.